Key Highlights

● Shares closed at $120.25 at their last session, up 3.37% on the day.

● iRhythm reported second-quarter 2026 Revenue of about $224.2 million, up about 20.1% year over year, with gross Margin improving to about 72.8%.

● The company agreed to acquire VitalConnect for about $287.5 million to expand its cardiac-monitoring capabilities into new care settings.

● iRhythm raised its full-year outlook to about $880 million to $890 million in revenue and reached a near-breakeven GAAP net loss of about $0.4 million.

iRhythm Holdings (NASDAQ:IRTC) shares closed at $120.25 at their last session, up 3.37% on the day, as the maker of wearable cardiac-monitoring devices led by its Zio system delivered strong revenue growth, expanding margins and near-breakeven results, and announced an Acquisition to broaden its platform. For investors, the question is what to watch next for a company scaling its ambulatory cardiac-monitoring Business toward sustained profitability.

iRhythm provides ambulatory cardiac monitoring through its Zio devices and services, which continuously record a patient's heart rhythm to detect arrhythmias, generating revenue as physicians prescribe its monitoring.

Latest Developments

In its second-quarter 2026 results, iRhythm reported revenue of about $224.2 million, up about 20.1% year over year, with gross margin improving to about 72.8% and a near-breakeven GAAP net loss of about $0.4 million (versus a larger loss a year earlier). Adjusted EBITDA reached about $43.3 million (a 19.3% margin), reflecting operating leverage.

The company agreed to acquire VitalConnect for about $287.5 million (roughly $237.5 million cash and $50 million stock), expected to close by year-end 2026, to expand its cardiac-monitoring capabilities across ambulatory, inpatient and hospital-to-home settings, and it raised its full-year outlook to about $880 million to $890 million in revenue. It held about $591.3 million in cash and securities.

Financial and Business Position

iRhythm's strong, volume-led revenue growth, expanding gross margin and near-breakeven results reflect the scaling of its leading Zio cardiac-monitoring Franchise and improving operating leverage, and the planned VitalConnect acquisition would broaden its platform into additional care settings.

Stock-Market Context

Shares closed at $120.25 at their last session, up 3.37% on the day. The stock carries a strong-buy rating, and the recent gain reflects the strong results and the acquisition news. The forward case rests on continued volume-led revenue growth, gross-margin expansion, successful integration of VitalConnect, and progress to sustained profitability. The cautionary case is the acquisition integration and cost.

Scale Translating Into Profitability

iRhythm's quarter reinforced its standing as the leader in ambulatory cardiac monitoring, a business with attractive characteristics and a clear runway. Its Zio system, a wearable patch that continuously records a patient's heart rhythm to detect arrhythmias, drove roughly 20% volume-led revenue growth, and the Operating Leverage was striking: gross margin expanded toward 73% and the company reached near-breakeven on a GAAP basis, a marked improvement that shows scale is translating into profitability.

The agreement to acquire VitalConnect for about $287.5 million is strategically significant, extending iRhythm's reach beyond ambulatory monitoring into inpatient and hospital-to-home settings and broadening the platform of a company that has largely defined its category.

Investors watching this story will want to see Zio volume-led growth and margin expansion continue while VitalConnect closes and integrates smoothly. For investors, the decisive factors are whether iRhythm converts its market leadership into a durably profitable, broader cardiac-monitoring franchise rather than a single-product growth story.